A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog

Journal of Controlled Release

Volumn 160, Issue 3, 2012, Pages 468-476

  Christensen, Dennis ^a   Henriksen Lacey, Malou ^b   Kamath, Arun T ^c   Lindenstrøm, Thomas ^a   Korsholm, Karen S ^a   Christensen, Jan P ^d   Rochat, Anne Francoise ^c   Lambert, Paul Henri ^c   Andersen, Peter ^a   Siegrist, Claire Anne ^c   Perrie, Yvonne ^b   Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvant; DDA; Depot effect; Dimethyldioctadecylammonium; Dimethyldioleoylammonium; DODA

Indexed keywords

ADJUVANT; DEPOT EFFECT; DIMETHYLDIOCTADECYLAMMONIUM; DIMETHYLDIOLEOYLAMMONIUM; DODA;

ANTIGENS; CELLS; CYTOLOGY; DIGITAL DIFFERENTIAL ANALYZERS; IMMUNOLOGY; LIPOSOMES; MOLECULES;

VACCINES;

ADJUVANT; ANTIGEN 85B; CD40 ANTIGEN; CD86 ANTIGEN; DIMETHYLDIOCTADECYLAMMONIUM; DIMETHYLDIOLEOYLAMMONIUM; EARLY SECRETORY ANTIGENIC TARGET 6; LIPID; LIPOSOME; QUATERNARY AMMONIUM DERIVATIVE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; INJECTION SITE; LYMPH NODE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TH1 CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCOLIPIDS; KINETICS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; VACCINES;

EID: 84861990258     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.03.016     Document Type: Article

References (70)

1. T. Nakanishi, J. Kunisawa, A. Hayashi, Y. Tsutsumi, K. Kubo, S. Nakagawa, H. Fujiwara, T. Hamaoka, T. Mayumi, Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins, Biochem. Biophys. Res. Commun. 240 (1997) 793-797. (Pubitemid 28271799)
2. A. Joseph, N. Itskovitz-Cooper, S. Samira, O. Flasterstein, H. Eliyahu, D. Simberg, I. Goldwaser, Y. Barenholz, E. Kedar, A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice, Vaccine 24 (2006) 3990-4006.
3. Y. Perrie, P.M. Frederik, G. Gregoriadis, Liposome-mediated DNA vaccination: the effect of vesicle composition, Vaccine 19 (2001) 3301-3310. (Pubitemid 32324062)
4. M. Henriksen-Lacey, D. Christensen, V.W. Bramwell, T. Lindenstrom, E.M. Agger, P. Andersen, Y. Perrie, Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response, J. Control. Release 8 (2010) 153-161.
5. M. Henriksen-Lacey, A. Devitt, Y. Perrie, The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production, J. Control. Release 154 (2011) 131-137.
6. Y. Nakano, M. Mori, S. Nishinohara, Y. Takita, S. Naito, H. Kato, M. Taneichi, K. Komuro, T. Uchida, Surface-linked liposomal antigen induces IgE-selective unresponsiveness regardless of the lipid components of liposomes, Bioconjug. Chem. 12 (2001) 391-395. (Pubitemid 32464185)
7. T. Yasuda, G.F. Dancey, S.C. Kinsky, Immunogenic properties of liposomal model membranes in mice, J. Immunol. 119 (1977) 1863-1867. (Pubitemid 8232073)
8. T. Yasuda, G.F. Dancey, S.C. Kinsky, Immunogenicity of liposomalmodelmembranes in mice: dependence on phospholipid composition, PNAS 74 (1977) 1234-1236. (Pubitemid 8065640)
9. O. Bakouche, D. Gerlier, Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition, Immunology 58 (1986) 507-513. (Pubitemid 16097653)
10. A.J. van Houte, H. Snippe, M.G. Schmitz, J.M. Willers, Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V. Effect of membrane composition on humoral and cellular immunogenicity, Immunology 44 (1981) 561-568. (Pubitemid 11028012)
11. D. Gall, The adjuvant activity of aliphatic nitrogenous bases, Immunology 11 (1966) 369-386.
12. T. Mazumdar, K. Anam, N. Ali, Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens, J. Parasitol. 91 (2005) 269-274. (Pubitemid 40756261)
13. G.F. Dancey, T. Yasuda, S.C. Kinsky, Effect of liposomal model membrane composition on immunogenicity, J. Immunol. 120 (1978) 1109-1113. (Pubitemid 8343805)
14. P. Andersen, The T cell response to secreted antigens of Mycobacterium tuberculosis, Immunobiology 191 (1994) 537-547. (Pubitemid 24331480)
15. D. Katz, S. Lehrer, O. Galan, B. Lachmi, S. Cohen, I. Inbar, I. Samina, B. Peleg, D. Heller, H. Yadin, D. Chai, E. Freeman, H. Schupper, P. Fuchs, Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines, Adv. Exp. Med. Biol. 397 (1996) 115-125. (Pubitemid 26066568)
16. C. Klinguer-Hamour, C. Libon, H. Plotnicky-Gilquin, M.-C. Bussat, L. Revy, T. Nguyen, J.-Y. Bonnefoy, N. Corvaia, A. Beck, DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine, Vaccine 20 (2002) 2743-2751. (Pubitemid 34597135)
17. C.A. Kraaijeveld, G. la Riviere, B.J. Benaissa-Trouw, J. Jansen, T. Harmsen, H. Snippe, Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus, Antiviral Res. 3 (1983) 137-149. (Pubitemid 14226668)
18. E.B. Lindblad, M.J. Elhay, R. Silva, R. Appelberg, P. Andersen, Adjuvant modulation of immune responses to tuberculosis subunit vaccines, Infect. Immun. 65 (1997) 623-629. (Pubitemid 27053234)
19. L.A. Hilgers, H. Snippe, DDA as an immunological adjuvant, Res. Immunol. 143 (1992) 494-503 (discussion 574-496).
20. M. Henriksen-Lacey, V.W. Bramwell, D. Christensen, E.M. Agger, P. Andersen, Y. Perrie, Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen, J. Control. Release 142 (2010) 180-186.
21. L.A. Hilgers, H. Snippe, M. Jansze, J.M. Willers, Combinations of two synthetic adjuvants: synergistic effects of a surfactant and a polyanion on the humoral immune response, Cell. Immunol. 92 (1985) 203-209. (Pubitemid 15031559)
22. K.S. Korsholm, E.M. Agger, C. Foged, D. Christensen, J. Dietrich, C.S. Andersen, C. Geisler, P. Andersen, The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes, Immunology 121 (2007) 216-226. (Pubitemid 46663090)
23. E.M. Agger, I. Rosenkrands, J. Hansen, K. Brahimi, B.S. Vandahl, C. Aagaard, K. Werninghaus, C. Kirschning, R. Lang, D. Christensen, M. Theisen, F. Follmann, P. Andersen, Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements, PLoS One 3 (2008) e3116.
24. H. Schoenen, B. Bodendorfer, K. Hitchens, S. Manzanero, K. Werninghaus, F. Nimmerjahn, E.M. Agger, S. Stenger, P. Andersen, J. Ruland, G.D. Brown, C. Wells, R. Lang, Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate, J. Immunol. 184 (2010) 2756-2760.
25. K. Werninghaus, A. Babiak, O. Gross, C. Holscher, H. Dietrich, E.M. Agger, J. Mages, A. Mocsai, H. Schoenen, K. Finger, F. Nimmerjahn, G.D. Brown, C. Kirschning, A. Heit, P. Andersen, H. Wagner, J. Ruland, R. Lang, Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcR {gamma}-Syk-Card9-dependent innate immune activation, J. Exp. Med. 206 (2009) 89-97.
26. J. Davidsen, I. Rosenkrands, P. Andersen, Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids, Statens Serum Institut, WO2006002642, 2006.
27. J. Davidsen, I. Rosenkrands, D. Christensen, A. Vangala, D. Kirby, Y. Perrie, E.M. Agger, P. Andersen, Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses, Biochim. Biophys. Acta 1718 (2005) 22-31. (Pubitemid 41698893)
28. A. Weinrich Olsen, L.A. van Pinxteren, L. Meng Okkels, P. Birk Rasmussen, P. Andersen, Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6, Infect. Immun. 69 (2001) 2773-2778. (Pubitemid 32332164)
29. P. Andersen, D. Askgaard, L. Ljungqvist, M.W. Bentzon, I. Heron, T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis, Infect. Immun. 59 (1991) 1558-1563.
30. E.M. Agger, J.P. Cassidy, J. Brady, K.S. Korsholm, C. Vingsbo-Lundberg, P. Andersen, Adjuvant-modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection, Immunology 124 (2008) 175-185. (Pubitemid 351692898)
31. I. Rosenkrands, E.M. Agger, A.W. Olsen, K.S. Korsholm, C.S. Andersen, K.T. Jensen, P. Andersen, Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system, Infect. Immun. 73 (2005) 5817-5826. (Pubitemid 41193018)
32. T. Lindenstrom, E.M. Agger, K.S. Korsholm, P.A. Darrah, C. Aagaard, R.A. Seder, I. Rosenkrands, P. Andersen, Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells, J. Immunol. 182 (2009) 8047-8055.
33. N.L. Tilney, Patterns of lymphatic drainage in the adult laboratory rat, J. Anat. 109 (1971) 369-383.
34. A.T. Kamath, A.F. Rochat, D. Christensen, E.M. Agger, P. Andersen, P.H. Lambert, C.A. Siegrist, A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells, PLoS One 4 (2009) e5771.
35. A.T. Kamath, A.F. Rochat, M.P. Valenti, E.M. Agger, K. Lingnau, P. Andersen, P.H. Lambert, C.A. Siegrist, Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant, PLoS One 3 (2008) e3683.
36. R.A. Seder, P.A. Darrah, M. Roederer, T-cell quality in memory and protection: implications for vaccine design, Nat. Rev. Immunol. 8 (2008) 247-258. (Pubitemid 351432801)
37. M.W. Munks, A.S. McKee, M.K. Macleod, R.L. Powell, J.L. Degen, N.A. Reisdorph, J.W. Kappler, P. Marrack, Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo, Blood 116 (2010) 5191-5199.
38. R.L. Richards, M. Rao, T.C. Vancott, G.R. Matyas, D.L. Birx, C.R. Alving, Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen, Immunol. Cell Biol. 82 (2004) 531-538. (Pubitemid 39421063)
39. G. Iezzi, K. Karjalainen, A. Lanzavecchia, The duration of antigenic stimulation determines the fate of naive and effector T cells, Immunity 8 (1998) 89-95. (Pubitemid 28097826)
40. P. Johansen, T. Storni, L. Rettig, Z. Qiu, A. Der-Sarkissian, K.A. Smith, V. Manolova, K.S. Lang, G. Senti, B. Mullhaupt, T. Gerlach, R.F. Speck, A. Bot, T.M. Kundig, Antigen kinetics determines immune reactivity, PNAS 105 (2008) 5189-5194. (Pubitemid 351738532)
41. S. Lofthouse, Immunological aspects of controlled antigen delivery, Adv. Drug Deliv. Rev. 54 (2002) 863-870. (Pubitemid 35284015)
42. R.M. Zinkernagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig, H. Hengartner, Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity, Immunol. Rev. 156 (1997) 199-209. (Pubitemid 27197203)
43. B. Hansen, A. Sokolovska, H. HogenEsch, S.L. Hem, Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response, Vaccine 25 (2007) 6618-6624. (Pubitemid 47211514)
44. S.L. Hem, H. Hogenesch, Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation, Expert Rev. Vaccines 6 (2007) 685-698. (Pubitemid 47607846)
45. R. Obst, H.M. van Santen, R. Melamed, A.O. Kamphorst, C. Benoist, D. Mathis, Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation, PNAS 104 (2007) 15460-15465. (Pubitemid 47502939)
46. M. Henriksen-Lacey, K.S. Korsholm, P. Andersen, Y. Perrie, D. Christensen, Liposomal vaccine delivery systems, Expert Opin. Drug Deliv. 8 (2011) 505-519.
47. M. Henriksen-Lacey, D. Christensen, V.W. Bramwell, T. Lindenstrom, E.M. Agger, P. Andersen, Y. Perrie, Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3beta-[N-(N′, N′- Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses, Mol. Pharm. 8 (2011) 153-161.
48. A. Glenny, C. Pope, H. Waddington, U. Wallace, The antigenic value of toxoid precipitated by potassium alum, J. Pathol. Bacteriol. 29 (1926) 38-45.
49. S.M. Noe, M.A. Green, H. HogenEsch, S.L. Hem, Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response, Vaccine 28 (2010) 3588-3594.
50. I.Z. Romero Mendez, Y. Shi, H. HogenEsch, S.L. Hem, Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants, Vaccine 25 (2007) 825-833. (Pubitemid 44856127)
51. S. Hutchison, R.A. Benson, V.B. Gibson, A.H. Pollock, P. Garside, J.M. Brewer, Antigen depot is not required for alum adjuvanticity, FASEB J. 26 (2011) 1272-1279.
52. P. Marrack, A.S. McKee, M.W. Munks, Towards an understanding of the adjuvant action of aluminium, Nat. Rev. Immunol. 9 (2009) 287-293.
53. J.M. Kemp, M. Kajihara, S. Nagahara, A. Sano, M. Brandon, S. Lofthouse, Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses, Vaccine 20 (2002) 1089-1098. (Pubitemid 34135944)
54. S.A. Lofthouse, M. Kajihara, S. Nagahara, A. Nash, G.J. Barcham, B. Sedgmen, M.R. Brandon, A. Sano, Injectable silicone implants as vaccine delivery vehicles, Vaccine 20 (2002) 1725-1732. (Pubitemid 34242827)
55. J. Myschik, F. Eberhardt, T. Rades, S. Hook, Immunostimulatory biodegradable implants containing the adjuvant Quil-A - Part I: physicochemical characterisation, J. Drug Target. 16 (2008) 213-223. (Pubitemid 351460650)
56. J. Myschik, W.T. McBurney, T. Hennessy, A. Phipps-Green, T. Rades, S. Hook, Immunostimulatory biodegradable implants containing the adjuvant Quil-A - part II: In vivo evaluation, J. Drug Target. 16 (2008) 224-232. (Pubitemid 351460651)
57. R. Kaur, V.W. Bramwell, D.J. Kirby, Y. Perrie, Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses, J. Control. Release 158 (2011) 72-77.
58. C. Schellack, K. Prinz, A. Egyed, J.H. Fritz, B. Wittmann, M. Ginzler, G. Swatosch, W. Zauner, C. Kast, S. Akira, A. von Gabain, M. Buschle, K. Lingnau, IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses, Vaccine 24 (2006) 5461-5472. (Pubitemid 43831376)
59. F.A. Harding, J.G. McArthur, J.A. Gross, D.H. Raulet, J.P. Allison, CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature 356 (1992) 607-609.
60. D. Hawiger, K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J.V. Ravetch, R.M. Steinman, M.C. Nussenzweig, Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo, J. Exp. Med. 194 (2001) 769-779. (Pubitemid 32983013)
61. S. Hugues, Dynamics of dendritic cell-T cell interactions: a role in T cell outcome, Semin. Immunopathol. 32 (2010) 227-238.
62. R.H. Schwartz, T cell anergy, Annu. Rev. Immunol. 21 (2003) 305-334. (Pubitemid 37174534)
63. T.H. Watts, Staying Alive: T Cell Costimulation, CD28, and Bcl-xL, J. Immunol. 185 (2010) 3785-3787.
64. A.T. Kamath, B. Mastelic, D. Christensen, A.F. Rochat, E.M. Agger, P. Andersen, D.D. Pinschewer, P.H. Lambert, C.A. Siegrist, Synchronization of DC activation and antigen exposure is required for the induction of Th1/Th17 responses, J. Immunol. 188 (2012) 4828-4837.
65. T. Tanaka, A. Legat, E. Adam, J. Steuve, J.S. Gatot, M. Vandenbranden, L. Ulianov, C. Lonez, J.M. Ruysschaert, E. Muraille, M. Tuynder, M. Goldman, A. Jacquet, DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4, Eur. J. Immunol. 38 (2008) 1351-1357.
66. W. Yan, W. Chen, L. Huang, Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines, Mol. Immunol. 44 (2007) 3672-3681. (Pubitemid 46817670)
67. L. Holten-Andersen, T.M. Doherty, K.S. Korsholm, P. Andersen, Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines, Infect. Immun. 72 (2004) 1608-1617. (Pubitemid 38263784)
68. L. Brandt, M. Elhay, I. Rosenkrands, E.B. Lindblad, P. Andersen, ESAT-6 Subunit vaccination against Mycobacterium tuberculosis, Infect. Immun. 68 (2000) 791-795. (Pubitemid 30056537)
69. C.A. Andersen, I. Rosenkrands, A.W. Olsen, P. Nordly, D. Christensen, R. Lang, C. Kirschning, J.M. Gomes, V. Bhowruth, D.E. Minnikin, G.S. Besra, F. Follmann, P. Andersen, E.M. Agger, Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guerin, J. Immunol. 183 (2009) 2294-2302.
70. P. Nordly, K.S. Korsholm, E.A. Pedersen, T.S. Khilji, H. Franzyk, L. Jorgensen, H.M. Nielsen, E.M. Agger, C. Foged, Incorporation of a syntheticmycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo, Eur. J. Pharm. Biopharm. 77 (2011) 89-98.